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In The Lancet, Kathy Pritchard-Jones and colleagues1 
from the International Society of Paediatric Oncology 
(SIOP) report results from their Wilms’ tumour 2001 
randomised, controlled, non-inferiority study. They 
recruited 583 children aged 6 months to 18 years with 
stage II–III, histological intermediate-risk Wilms’ tumour 
who had received 4 weeks of preoperative chemotherapy 
with vincristine and actinomycin D. They randomly 
assigned the children (1:1) by a minimisation technique 
to receive either postnephrectomy combination chemo-
therapy with vincristine and actinomycin D alone—
the experimental treatment—or these two drugs plus 
doxorubicin (a cardiotoxic chemotherapeutic drug),2–4 
the standard treatment. The primary endpoint was 
non-inferiority of event-free survival at 2 years, analysed 
by intention to treat with a margin of 10%. With a 
median follow-up of 60·8 months (IQR 40·8–79·8), 
2-year event-free survival was 92·6% (95% CI 89·6–95·7) 
for treatment including doxorubicin and 88·2% 
(84·5–92·1) for treatment excluding doxorubicin, a 
diﬀ erence of 4·4% (95% CI 0·4–9·3) that did not exceed 
the predeﬁ ned inferiority margin. Pritchard-Jones and 
colleagues conclude that when the histological response 
to the brief period of prenephrectomy chemotherapy 
is incorporated into the risk stratiﬁ cation—with an 
in-vivo chemosensitivity assay of each individual tumour 
using the SIOP Wilms’ tumour pathology deﬁ nitions5—
postnephrectomy chemotherapy can be reduced and 
might not need to include doxorubicin (however, they 
acknowledge that a few additional children might need 
full treatment for relapse).
Pritchard-Jones and colleagues’ study1 is valuable 
because the ﬁ ndings suggest that doxorubicin might 
not be needed for the treatment of a substantial new 
subgroup of children with Wilms’ tumour. This result 
is, however, dependent upon the accurate diagnosis 
of intermediate-risk histology. The risk of generalising 
these results to children with stage II–III, histological 
intermediate-risk Wilms’ tumour is that some (2% 
in Pritchard-Jones and colleagues’ study) will still be 
high risk (as determined by histology) after central 
pathological review, and will be undertreated if 
chemotherapy with only two drugs is continued.
The more important limitation of Pritchard-Jones and 
colleagues’ ﬁ ndings is that they apply only to children 
who receive prenephrectomy chemotherapy with 
vincristine and actinomycin D. Many children in North 
America and elsewhere routinely undergo immediate 
nephrectomy for a suspected Wilms’ tumour, which 
is a decision based on the preference to treat them 
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Leder and colleagues’ elegant study6 provides important 
data to guide sequential osteoporosis therapy and 
supports the concept of selection of an osteoanabolic 
boost, followed by an antiresorptive therapy to 
consolidate BMD gains in high-risk patients requiring 
long-term osteoporosis treatment.
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using more accurate surgical–pathological staging 
information. An earlier SIOP study6 was closed because 
of an excess of intra-abdominal relapses, which suggests 
that prenephrectomy chemotherapy might have altered 
the accuracy of pathological-staging assessments 
after nephrectomy. Although the randomisation 
proportion of 583 (69%) of the 845 eligible patients 
conﬁ rmed as intermediate-risk with histology would 
generally be regarded as excellent for a group-wide 
trial, details about the clinical characteristics for those 
randomly assigned to treatment compared with those 
not randomly assigned (such as institutional tumour 
stage, both pretreatment and prenephrectomy tumour 
volume, institutional favourable subtype as determined 
with histology) were not included in the manuscript. 
Although obtaining data about patients who are 
eligible for a trial but might not, for various reasons, be 
included in the randomisation is challenging, in a trial 
such as SIOP Wilms’ tumour 2001, where all patients 
were registered for follow-up, the additional cost 
for obtaining these data would have been worth the 
expense as they would have helped with interpreting 
the generalisability of the study’s ﬁ ndings. 
Although the data from Pritchard-Jones and 
colleagues’ study1 cannot be extrapolated to patients 
with Wilms’ tumour who undergo an immediate 
nephrectomy, assessment of long-term results from 
the National Wilms Tumor Studies 2 and 37,8 have 
suggested that the addition of doxorubicin to vincristine 
and actinomycin D does not improve the relapse-free 
survival rate for patients with stage III, favourable-
histology Wilms’ tumour, as assessed with the National 
Wilms Tumor Study pathology system.9 A beneﬁ t of 
doxorubicin was never shown for those with stage II, 
favourable-histology Wilms’ tumour.7,10
Therefore, Pritchard-Jones and colleagues’ inter-
pretation of their results is appropriately cautious. 
However, they have taken a much-needed step that has 
application in other paediatric-oncology settings. They 
make us ask several questions: how much short-term 
beneﬁ t in event-free survival is necessary to justify 
intensiﬁ cation of therapy in a cohort of children that, 
without intensiﬁ cation, has an excellent event-free 
survival rate? When is it appropriate to expose all 
participants of a patient cohort to a more intensive 
treatment regimen when the projected improvement 
in event-free survival is only 5–10%?
When the intensiﬁ cation involves the addition of a 
drug with a high risk of cardiomyopathy,11 oligospermia, 
or azoospermia,12 to the treatment management of 
every child, what guidelines should be adopted to 
determine when such intensiﬁ cation is justiﬁ ed? Should 
future therapeutic research for small groups of children 
be directed towards the development of more eﬀ ective 
relapse treatments for the few who relapse, which would 
restrict any exposure to serious toxic drug side-eﬀ ects to 
the population of patients who are most likely to derive 
beneﬁ t from intensiﬁ ed therapy? Pritchard-Jones and 
her colleagues are to be congratulated for taking a risk in 
their study and showing that, within the restrictions of 
their statistical design, omission of a chemotherapeutic 
agent that would produce cardiac injury, albeit 
subclinical in the short term, did not result in an inferior 
outcome in most patients who were treated.11
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